Elizabeth Trice Loggers, MD, PhD
Assistant Investigator
206-442-5222
loggers.e@ghc.org
Recent publications
Curriculum vitae (CV)
Research interests and experience
- End-of-life care: quality of care; communication; racial disparities
- Cancer control: quality of life; health outcomes; end-of-life care; participation in clinical trials; Hispanic acculturation and cancer outcomes; geriatrics; patient/provider interaction
- Health services & economics: primary care delivery and cancer outcomes; intensity and cost of care; comparative effectiveness analyses
- Rare cancers: treatment variability and outcomes; end-of-life care
Elizabeth Trice Loggers joined Group Health Research Institute in 2009 after completing a fellowship in the Department of Medical Oncology at the Dana-Farber Cancer Institute (DFCI). Her research while at the Center for Psycho-oncology and Palliative Care Research at DFCI focused primarily on communication and end-of-life care for advanced cancer patients, with an emphasis on racial and ethnic differences. Her position as assistant investigator is a joint appointment with the Clinical Research Division of Fred Hutchinson Cancer Research Center. Dr. Loggers maintains a part-time clinical practice at Seattle Cancer Care Alliance where she specializes in the treatment of individuals with sarcoma (i.e., cancers of the bone, muscles, nerves, or vessels) and is the Medical Director for Palliative Care.
Recent publications
Loggers ET, Starks H, Shannon-Dudley M, Back AL, Appelbaum FR, Stewart FM. Implementing a Death with Dignity program at a comprehensive cancer center. N Engl J Med. 2013 Apr 11;368(15):1417-24. doi: 10.1056/NEJMsa1213398.
Calip GS, Boudreau DM, Loggers ET. Changes in adherence to statins and subsequent lipid profiles during and following breast cancer treatment. Breast Cancer Res Treat. 2013 Feb;138(1):225-33. doi: 10.1007/s10549-013-2424-2. Epub 2013 Jan 29. PubMed
Spangler L, Yu O, Loggers E, Boudreau DM. Bone mineral density screening among women with a history of breast cancer treated with aromatase inhibitors. J Womens Health (Larchmt). 2013;22(2):132-40. doi: 10.1089/jwh.2012.3687. PubMed
Ritzwoller DP, Carroll N, Delate T, Hornbrook MC, Kushi L, Aiello Bowles EJ, Freml JM, Huang K, Loggers ET. Patterns and predictors of first-line chemotherapy use among adults with advanced non-small cell lung cancer in the Cancer Research Network. Lung Cancer. 2012 Dec;78(3):245-52. doi: 10.1016/j.lungcan.2012.09.008. Epub 2012 Sep 27.
Hu Y, Kwok AC, Jiang W, Taback N, Loggers ET, Ting GV, Lipsitz SR, Weeks JC, Greenberg CC. High-Cost Imaging in Elderly Patients with Stage IV Cancer. J Natl Cancer Inst. 2012 Aug 8;104(15):1164-72. Epub 2012 Jul 31. PubMed
Lowry SJ, Loggers ET, Bowles EJ, Wagner EH. Evidence gaps in advanced cancer care: community-based clinicians' perspectives and priorities for CER. Am J Manag Care. 2012;18(5 Spec No. 2):SP77-83. PubMed
Lowry SJ, Loggers ET, Bowles EJ, Wagner EH. Evidence gaps in advanced cancer care: community-based clinicians' perspectives and priorities for comparative effectiveness research. J Oncol Pract. 2012 May;8(3 Suppl):28s-33s.
Ritzwoller DP, Carroll N, Delate T, O'Keeffe-Rossetti M, Fishman PA, Loggers ET, Aiello Bowles EJ, Elston-Lafata J, Hornbrook MC. Validation of electronic data on chemotherapy and hormone therapy use in HMOs. Med Care. 2012 Apr 23 [Epub ahead of print] PubMed
Talcott JA, Yeap BY, Clark JA, Siegel RD, Loggers ET, Lu C, Godley PA. Safety of early discharge for low-risk patients with febrile neutropenia: a multicenter randomized controlled trial. J Clin Oncol. 2011 Oct 20;29(30):3977-83. Epub 2011 Sep 19.
Hendricks AM, Loggers ET, Talcott JA. The costs of home versus inpatient treatment for fever and neutropenia: analysis of a multicenter randomized trial. J Clin Oncol. 2011 Oct 20;29(30):3984-9. doi: 10.1200/JCO.2011.35.1247. Epub 2011 Sep 19.
To view more publications, please see Dr. Logger’s CV.